Department of Radiology (V.Z., W.H., T.Q.D.), Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York.
Department of Medicine, Nephrology Division (M.F.), Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York.
Hypertension. 2023 Oct;80(10):2135-2148. doi: 10.1161/HYPERTENSIONAHA.123.21174. Epub 2023 Aug 21.
SARS-CoV-2 may trigger new-onset persistent hypertension. This study investigated the incidence and risk factors associated with new-onset persistent hypertension during COVID-19 hospitalization and at ≈6-month follow-up compared with influenza.
This retrospective observational study was conducted in a major academic health system in New York City. Participants included 45 398 patients with COVID-19 (March 2020 to August 2022) and 13 864 influenza patients (January 2018 to August 2022) without a history of hypertension.
At 6-month follow-up, new-onset persistent hypertension was seen in 20.6% of hospitalized patients with COVID-19 and 10.85% of nonhospitalized patients with COVID-19. Persistent hypertension incidence among hospitalized patients did not vary across the pandemic, whereas that of hospitalized patients decreased from 20% in March 2020 to ≈10% in October 2020 (R=0.79, =0.003) and then plateaued thereafter. Hospitalized patients with COVID-19 were 2.23 ([95% CI, 1.48-3.54]; <0.001) times and nonhospitalized patients with COVID-19 were 1.52 ([95% CI, 1.22-1.90]; <0.01) times more likely to develop persistent hypertension than influenza counterparts. Persistent hypertension was more common among older adults, males, Black, patients with preexisting comorbidities (chronic obstructive pulmonary disease, coronary artery disease, chronic kidney disease), and those who were treated with pressor and corticosteroid medications. Mathematical models predicted persistent hypertension with 79% to 86% accuracy. In addition, 21.0% of hospitalized patients with COVID-19 with no prior hypertension developed hypertension during COVID-19 hospitalization.
Incidence of new-onset persistent hypertension in patients with COVID-19 is higher than those with influenza, likely constituting a major health burden given the sheer number of patients with COVID-19. Screening at-risk patients for hypertension following COVID-19 illness may be warranted.
SARS-CoV-2 可能引发新发持续性高血压。本研究旨在调查 COVID-19 住院期间及 ≈6 个月随访时与流感相比新发持续性高血压的发生率和相关风险因素。
这是一项在纽约市一家主要学术医疗系统中进行的回顾性观察性研究。参与者包括 45398 例 COVID-19 住院患者(2020 年 3 月至 2022 年 8 月)和 13864 例流感住院患者(2018 年 1 月至 2022 年 8 月),且均无高血压病史。
COVID-19 住院患者中,6 个月随访时新发持续性高血压发生率为 20.6%,非住院 COVID-19 患者为 10.85%。COVID-19 住院患者持续性高血压的发生率在整个大流行期间无差异,而 2020 年 3 月住院患者的发生率从 20%下降至 2020 年 10 月的 ≈10%(R=0.79,=0.003),此后趋于平稳。COVID-19 住院患者发生持续性高血压的风险是非流感住院患者的 2.23 倍(95%CI,1.48-3.54),差异有统计学意义(<0.001);非住院 COVID-19 患者发生持续性高血压的风险是非流感住院患者的 1.52 倍(95%CI,1.22-1.90),差异有统计学意义(<0.01)。持续性高血压在老年患者、男性、黑人、合并有慢性阻塞性肺疾病、冠心病、慢性肾脏病等合并症患者以及接受升压和皮质激素治疗的患者中更为常见。数学模型预测持续性高血压的准确率为 79%至 86%。此外,21.0%的 COVID-19 住院患者在 COVID-19 住院期间原本无高血压病史,但出现了高血压。
COVID-19 患者新发持续性高血压的发生率高于流感患者,鉴于 COVID-19 患者的数量庞大,这可能构成一个主要的健康负担。COVID-19 后对高血压高危患者进行筛查可能是必要的。